Elevated serum sialyl Lewis X-i antigen levels in non-small cell lung cancer with lung metastasis.

Abstract

To evaluate the relationship between serum levels of sialyl Lewis X-i antigen and lung metastasis in patients with non-small cell lung cancer (NSCLC), we measured the serum level of the antigen in 299 patients with untreated locally advanced or metastatic NSCLC. Before treatment, serum levels of sialyl Lewis X-i antigen were significantly higher in patients with lung metastasis than in those without lung metastatis (p = 0.0001). Of 201 patients without lung metastasis at the time of primary diagnosis, 121 patients died between July 1987 and December 1995. Serum levels of sialyl Lewis X-i antigen in 21 patients who developed lung metastasis during the period were significantly higher than those in 100 patients who did not develop lung metastasis (p = 0.0171). Our results suggested that sialyl Lewis X-i antigen might be a good indicator for the presence or development of lung metastasis, and it might provide clinical information about the management of patients with NSCLC.

• Authors: H Satoh, H Ishikawa, H Kamma, Y T Yamashita, H Takahashi, M Ohtsuka, S Hasegawa
• Journal: Respiration; international review of thoracic diseases (Respiration) Vol. 65 Issue 4 Pg. 295-8 ( 1998) ISSN: 0025-7931 [Print] Switzerland
• PMID: 9730796 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• CA-19-9 Antigen

Topics

• Aged
• Biomarkers, Tumor (blood)
• CA-19-9 Antigen (blood)
• Carcinoma, Non-Small-Cell Lung (immunology, mortality, pathology)
• Female
• Humans
• Lung Neoplasms (immunology, mortality, pathology, secondary)
• Male
• Middle Aged
• Neoplasm Staging
• Radioimmunoassay
• Sensitivity and Specificity
• Statistics, Nonparametric
• Survival Rate